Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 972073, 7 pages
http://dx.doi.org/10.1155/2015/972073
Research Article

Inflammatory Cytokine Profile Associated with Metabolic Syndrome in Adult Patients with Type 1 Diabetes

1Endocrinology Department, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Cuauhtémoc 330, Colonia Doctores, 06720 Mexico City, MEX, Mexico
2Experimental Endocrinology Investigation Unit, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Cuauhtémoc 330, Colonia Doctores, 06720 Mexico City, MEX, Mexico
3Immunochemistry Medical Investigation Unit, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Cuauhtémoc 330, Colonia Doctores, 06720 Mexico City, MEX, Mexico

Received 15 December 2014; Revised 6 February 2015; Accepted 23 February 2015

Academic Editor: Alfredo Vannacci

Copyright © 2015 Aldo Ferreira-Hermosillo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. K. Wherrett and D. Daneman, “Prevention of Type 1 Diabetes,” Endocrinology and Metabolism Clinics of North America, vol. 38, no. 4, pp. 777–790, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. K. M. Gillespie, “Type 1 diabetes: pathogenesis and prevention,” CMAJ, vol. 175, no. 2, pp. 165–170, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. R. A. Gómez-Díaz, G. Peŕez-Pérez, I. T. Hernańdez-Cuesta et al., “Incidence of type 1 diabetes in Mexico: data from an institutional register 2000–2010,” Diabetes Care, vol. 35, no. 11, p. e77, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Ferreira-Hermosillo, G. Vargas-Ortega, B. González-Virla, M. Mercado-Atri, and M. Molina-Ayala, “Prevalence of metabolic syndrome (MS) in patients with diabetes mellitus type 1 (DM1),” Gaceta Médica de México, vol. 148, no. 2, pp. 137–143, 2012. View at Google Scholar · View at Scopus
  5. R. Rojas-Martínez, C. A. Aguilar-Salinas, A. Jiménez-Corona, F. J. Gómez-Pérez, S. Barquera, and E. Lazcano-Ponce, “Prevalence of obesity and metabolic syndrome components in Mexican adults without type 2 diabetes or hypertension,” Salud Pública de México, vol. 54, no. 1, pp. 7–12, 2012. View at Google Scholar · View at Scopus
  6. J. J. Chillarón, J. A. Flores-Le-Roux, A. Goday et al., “Metabolic syndrome and type-1 diabetes mellitus: prevalence and associated factors,” Revista Espanola de Cardiologia, vol. 63, no. 4, pp. 423–429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Teupe and K. Bergis, “Epidemiological evidence for ‘double diabetes’,” The Lancet, vol. 337, no. 8737, pp. 361–362, 1991. View at Google Scholar · View at Scopus
  8. G. Pambianco, T. Costacou, and T. J. Orchard, “The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience,” Diabetes Care, vol. 30, no. 5, pp. 1248–1254, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. S. S. Soedamah-Muthu, J. H. Fuller, H. E. Mulnier, V. S. Raleigh, R. A. Lawrenson, and H. M. Colhoun, “High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database,” Diabetes Care, vol. 29, no. 4, pp. 798–804, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. R. C. Bonadonna, D. Cucinotta, D. Fedele, G. Riccardi, and A. Tiengo, “The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey,” Diabetes Care, vol. 29, no. 12, pp. 2701–2707, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. L. M. Thorn, C. Forsblom, J. Wadén et al., “Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes,” Diabetes Care, vol. 32, no. 5, pp. 950–952, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. M. T. Schram, N. Chaturvedi, C. G. Schalkwijk, J. H. Fuller, and C. D. A. Stehouwer, “Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB Prospective Complications Study,” Diabetologia, vol. 48, no. 2, pp. 370–378, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. J. K. Snell-Bergeon, N. A. West, E. J. Mayer-Davis et al., “Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH case-control study,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 6, pp. 2868–2876, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Mahmoud and E. Al-Ozairi, “Inflammatory cytokines and the risk of cardiovascular complications in type 2 diabetes,” Disease Markers, vol. 35, no. 4, pp. 235–241, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Vidal-Puig and S. O'Rahilly, “Resistin: a new link between obesity and insulin resistance?” Clinical Endocrinology, vol. 55, no. 4, pp. 437–438, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. C. M. Steppan, S. T. Bailey, S. Bhat et al., “The hormone resistin links obesity to diabetes,” Nature, vol. 409, no. 6818, pp. 307–312, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. K. G. M. M. Alberti, R. H. Eckel, S. M. Grundy et al., “Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity,” Circulation, vol. 120, no. 16, pp. 1640–1645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. World Health Organization, “Obesity: preventing and managing the global epidemic. Report of a WHO consultation,” World Health Organization Technical Report Series 894, World Health Organization, Geneva, Switzerland, 2000. View at Google Scholar
  19. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972. View at Google Scholar · View at Scopus
  20. K. V. Williams, J. R. Erbey, D. Becker, S. Arslanian, and T. J. Orchard, “Can clinical factors estimate insulin resistance in type 1 diabetes?” Diabetes, vol. 49, no. 4, pp. 626–632, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. E. S. Kilpatrick, A. S. Rigby, and S. L. Atkin, “Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: ‘double diabetes’ in the diabetes control and complications trial,” Diabetes Care, vol. 30, no. 3, pp. 707–712, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Barquera, I. Campos-Nonato, L. Hernandez-Barrera, A. Pedroza, and J. A. Rivera-Dommarco, “Prevalence of obesity in Mexican adults 2000–2012,” Salud Publica de Mexico, vol. 55, supplement 2, pp. S151–S160, 2013. View at Google Scholar
  23. J. J. Chillaron, D. Benaiges, L. Mane, J. Pedro-Botet, and J. A. Flores Le-Roux, “Obesity and type 1 diabetes mellitus management,” Minerva Endocrinologica, vol. 40, no. 1, pp. 53–60, 2015. View at Google Scholar
  24. B. Conway, R. G. Miller, T. Costacou et al., “Temporal patterns in overweight and obesity in Type 1 diabetes,” Diabetic Medicine, vol. 27, no. 4, pp. 398–404, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Jager, V. W. M. van Hinsbergh, P. J. Kostense et al., “Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2: the hoorn study,” Diabetes, vol. 49, no. 3, pp. 485–491, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Jager, V. W. M. van Hinsbergh, P. J. Kostense et al., “von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 12, pp. 3071–3078, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. M. B. Schulze, I. Shai, E. B. Rimm, T. Li, N. Rifai, and F. B. Hu, “Adiponectin and future coronary heart disease events among men with type 2 diabetes,” Diabetes, vol. 54, no. 2, pp. 534–539, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. X. Provatopoulou, D. Georgiadou, T. N. Sergentanis et al., “Interleukins as markers of inflammation in malignant and benign thyroid disease,” Inflammation Research, vol. 63, pp. 667–674, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Tuttolomondo, R. Pecoraro, D. Di Raimondo et al., “Immune-inflammatory markers and arterial stiffness indexes in subjects with acute ischemic stroke with and without metabolic syndrome,” Diabetology & Metabolic Syndrome, vol. 6, no. 1, article 28, 2014. View at Publisher · View at Google Scholar
  30. G. Tian, J.-L. Li, D.-G. Wang, and D. Zhou, “Targeting IL-10 in Auto-immune Diseases,” Cell Biochemistry and Biophysics, vol. 70, no. 1, pp. 37–49, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. S. S. Pang and Y. Y. Le, “Role of resistin in inflammation and inflammation-related diseases,” Cellular & Molecular Immunology, vol. 3, no. 1, pp. 29–34, 2006. View at Google Scholar · View at Scopus
  32. H. C. Fehmann and J. Heyn, “Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls,” Hormone and Metabolic Research, vol. 34, no. 11-12, pp. 671–673, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Timar, B. Timar, D. Degeratu, C. Serafinceanu, and C. Oancea, “Metabolic syndrome, adiponectin and proinflammatory status in patients with type 1 diabetes mellitus,” Journal of International Medical Research, vol. 42, no. 5, pp. 1131–1138, 2014. View at Publisher · View at Google Scholar
  34. E. J. Epstein, J. L. Osman, H. W. Cohen, S. N. Rajpathak, O. Lewis, and J. P. Crandall, “Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes,” Diabetes Care, vol. 36, no. 8, pp. 2280–2285, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Mino and O. Takeuchi, “Post-transcriptional regulation of cytokine mRNA controls the initiation and resolution of inflammation,” Biotechnology and Genetic Engineering Reviews, vol. 29, no. 1, pp. 49–60, 2013. View at Publisher · View at Google Scholar · View at Scopus